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OBJECTIVE—To deﬁne the mechanisms underlying the accu-
mulation of monocytes/macrophages in the islets of Langerhans.
RESEARCH DESIGN AND METHODS—We tested the hy-
pothesis that macrophage accumulation into the islets is caused
by overexpression of the chemokine CCL2. To test this hypoth-
esis, we generated transgenic mice and evaluated the cellular
composition of the islets by immunohistochemistry and ﬂow
cytometry. We determined serum levels of CCL2 by enzyme-
linked immunosorbent assay, determined numbers of circulating
monocytes, and tested whether CCL2 could mobilize monocytes
from the bone marrow directly. We examined development of
diabetes over time and tested whether CCL2 effects could be
eliminated by deletion of its receptor, CCR2.
RESULTS—Expression of CCL2 by -cells was associated with
increased numbers of monocytes in circulation and accumula-
tion of macrophages in the islets of transgenic mice. These
changes were promoted by combined actions of CCL2 at the level
of the bone marrow and the islets and were not seen in animals
in which the CCL2 receptor (CCR2) was inactivated. Mice
expressing higher levels of CCL2 in the islets developed diabetes
spontaneously. The development of diabetes was correlated with
the accumulation of large numbers of monocytes in the islets and
did not depend on T- and B-cells. Diabetes could also be induced
in normoglycemic mice expressing low levels of CCL2 by increas-
ing the number of circulating myeloid cells.
CONCLUSIONS—These results indicate that CCL2 promotes
monocyte recruitment by acting both locally and remotely and
that expression of CCL2 by insulin-producing cells can lead to
insulitis and islet destruction. Diabetes 57:3025–3033, 2008
T
ype 1 diabetes is a chronic inﬂammatory disor-
der characterized by inﬁltration of the islets of
Langerhans by mononuclear cells and auto-
immune destruction of insulin-producing -cells
(1,2). Several lines of evidence suggest that macrophages
play a role in the development of diabetes. Macrophages
are the ﬁrst cells that appear within the islets of NOD mice
(3) and are also implicated in late phases of disease
development (4). Administration of clodronate-loaded
liposomes, which leads to disappearance of macro-
phages from the endocrine pancreas and periphery of
NOD mice, delays the onset of diabetes (5). Moreover,
macrophage depletion inhibits the development of
-cell–cytotoxic T-cells and prevents autoimmune dia-
betes (6). It has been suggested that the presentation of
self-antigens to autoreactive T-cells by dendritic cells
and macrophages recruited and activated by transgenic
tumor necrosis factor- (TNF-) expression accounts
for the development of diabetes (7). Macrophages and
dendritic cells are found within islets from recent-onset
type 1 diabetic patients (8).
Tissue macrophages originate from monocytes pro-
duced in the bone marrow. Current studies suggest that
bone marrow–derived monocytes give rise to two subsets
of peripheral blood monocytes (9). One subset (GR-1
,
CX3CR1
high, CCR2
, and CCL62L
 monocytes) gives ori-
gin to tissue macrophages (splenic macrophages, Kupffer
cells, alveolar macrophages, microglia, and osteoclasts).
The second subset (GR-1
, CX3CR1
low, CCR2
, and
CD62L
 monocytes) is preferentially recruited to inﬂamed
tissues and gives rise to macrophages and dendritic cells.
This inﬂammatory subset also expresses CD115 (granulo-
cyte macrophage colony–stimulating factor receptor) and
Ly6C (10,11).
Several studies implicate the chemokine CCL2 in mono-
cyte recruitment in vivo (12). CCL2 promotes recruitment
of monocytes, macrophages, dendritic cells, and activated
T-cells via its receptor, CCR2 (13). Numerous cell types,
including ﬁbroblasts, endothelial cells, epithelial cells,
leukocytes, and smooth muscle cells express CCL2 in the
presence of serum or speciﬁc stimuli (14,15). In addition to
chemotaxis, CCL2 contributes to activation of monocytes
and macrophages because CCL2 induces production of
TNF- and interleukin-1 in murine peritoneal macro-
phages (16). Macrophage recruitment caused by CCL2
expression has been strongly linked to several inﬂamma-
tory conditions, such as atherosclerosis (17), development
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and insulin resistance (19).
CCL2 expression has also been related to diabetes.
Primary cultures of murine and human pancreatic islets
express and secrete CCL2 (20). CCL2 expression has been
detected in islets of NOD mice during cyclophosphamide
treatment (21), and CCL2 expression parallels disease
progression in NOD mice (22,23). Low-level secretion of
CCL2 by islets before transplantation is associated with a
higher rate of insulin independence, suggesting an impor-
tant role for CCL2 in the clinical outcome of islet trans-
plantation in patients with type 1 diabetes (24).
Our laboratory and others have shown that CCL2 ex-
pression by insulin-producing cells induces the accumula-
tion of macrophages in the islets of transgenic mice
(25,26). We have also found that transgenic expression of
CCL2 induces migration of dendritic cells to the islets and
that the number of inﬂammatory cells recruited is depen-
dent on the levels of CCL2 produced by the -cells (26).
The mechanisms controlling accumulation of monocytes
in nonlymphoid tissues in response to increased levels of
CCL2 have not been examined. It is unclear whether the
accumulation of monocytes in inﬂamed tissues in re-
sponse to CCL2 reﬂects increased recruitment of circulat-
ing monocytes or monocyte precursors, changes in the
number of circulating monocytes, or both. Finally, it is
unclear whether changes in local levels of CCL2 may
promote development of diabetes.
Here, we show that transgenic expression of CCL2 by
insulin-producing cells is associated with changes in the
number of monocytes in circulation. The monocytes are
mobilized from the bone marrow in a CCR2-dependent
mechanism. We also found spontaneous development of
diabetes in two of the four transgenic lines expressing the
highest levels of CCL2 in the pancreas. The development
of diabetes required the accumulation of a large number of
monocytes in the islets and did not depend on T- or B-cells.
Animals expressing low levels of CCL2 in the islets did not
spontaneously develop diabetes but became diabetic if the
number of circulating monocytes was increased. These
results indicate that CCL2 promotes monocyte recruit-
ment by acting both locally and remotely and that dysregu-
lated expression of CCL2 by insulin-producing cells can
lead to insulitis and islet destruction.
RESEARCH DESIGN AND METHODS
RIPCCL2 mice were generated as described by Martin et al. (26) in B6D2
(C57BL/6  DBA) background. CCR2
/ mice were described by Boring et al.
(13). Rag-1
/ mice were obtained from The Jackson Laboratories (Bar
Harbor, ME). In all experiments, transgenic mice were compared with their
corresponding littermates. All mice were housed under speciﬁc pathogen-free
conditions in individually ventilated cages at the Mount Sinai School of
Medicine Animal Facility. All experiments were performed following institu-
tional guidelines.
Diabetes. The blood glucose was monitored weekly using a one-touch blood
Ascensia Contour glucometer (Bayer, Elkhart, IN). Animals were considered
diabetic when their blood glucose levels were 250 mg/dl in two consecutive
daily measurements.
Histology. Tissues for light microscopic examination were ﬁxed by immer-
sion in 10% phosphate-buffered formalin and then processed for parafﬁn
sections. Routinely, 5-m sections were cut and stained with hematoxylin-
eosin (H-E). For immunohistochemical staining, fresh frozen sections were
ﬁrst ﬁxed with ice-cold acetone for 20 min, dried, and stored at 20°C. Slides
were incubated for1ha troom temperature with puriﬁed primary antibodies
followed by incubation with the appropriate labeled secondary antibodies for
30 min. Primary antibodies used were anti-CD45 (550539), CD3 (550275),
CD11c (550283), B220 (550286), and CD11b (553308) from BD Biosciences
Pharmingen (San Diego, CA); F4/80 (MCAP497) from Serotec (Oxford, U.K.);
and guinea pig polyclonal anti-insulin (A0564) from Dako (Carpentaria, CA).
Secondary antibodies used were Alexa Fluor 488 and 594 goat anti-rat IgG
(A-11006 and A-11007) from Molecular Probes (Eugene, OR) and Cy3 goat
anti–Armenian hamster (127-165-160), ﬂuorescein isothiocyanate anti–guinea
pig IgG (706-095-148), and Cy5 goat anti-rat (112-175-167) from Jackson
ImmunoResearch (West Grove, PA).
To determine the degree of islet inﬁltration in RIPCCL2 mice, groups of
mice (n  5) were analyzed at 4 weeks of age. The total number of islets was
counted in each section (assessing 40–100 islets per animal), and semiquan-
titative analysis was performed on insulin/CD45-stained sections. Insulitis was
scored as follows: 0, no lesions; 1, peri-insular leukocytic aggregates; 2,
moderate insulitis with mononuclear cells inﬁltrating 	50% of the islet
architecture; and 3, severe insulitis with 50% of the islet tissue inﬁltrated by
mononuclear cells. An insulitis score for each mouse was obtained by dividing
the total score for each pancreas by the number of islets examined. Data are
presented as mean insulitis score 
 SE for the indicated experimental group.
In situ perfusion of femoral bone marrow. Female BALB/c mice were
anesthetized with urethane (25% 0.2 ml i.p.), and the femoral artery and vein
were exposed. The hind limb was isolated by occlusion of the external iliac
artery, superﬁcial epigastric, and muscular branch with 5/0 braided silk
suture. Polyethylene cannulae (0.61-mm outer diameter; Portex, London)
were immediately inserted into the femoral artery and vein and tied in place
with 5/0 braided silk suture. Perfusion buffer (modiﬁed Krebs-Ringer bicar-
bonate buffer) at 37°C was infused (0.15 ml/min) via the arterial cannula and
removed from the venous cannula using a Minipuls peristaltic pump
(Anachem, Luton, U.K.). The hind limb was perfused for an initial 10 min to
remove remaining blood from the vasculature and then perfused for a further
60 min with vehicle alone or 80 nmol/l CCL2 (250-10; Peprotech, London)
infused over the ﬁrst 20 min using an infusion/withdrawal pump (Harvard
Instruments, Edenbridge, U.K.). Resulting perfusate was kept on ice.
Intraperitoneal glucose tolerance test. After a 16-h fast, glucose (1.5 g/kg
body wt in saline [0.9% NaCl]) was administered intraperitoneally. The blood
glucose was monitored at 0, 30, 60, 120, and 240 min using a one-touch blood
Ascensia Contour glucometer (Bayer). The intraperitoneal glucose tolerance
test was performed on 8-week-old control and normoglycemic RIPCCL2 mice.
Isolation of pancreatic islets of Langerhans. Islets of Langerhans were
isolated as previously described (27). Brieﬂy, the common bile duct was
clamped distal to the pancreatic duct junction at its hepatic insertion. The
proximal common bile duct was then cannulated using a 27-gauge needle, and
the pancreas was infused by retrograde injection of 2 ml 1.0 mg/ml ice-cold
collagenase solution (Sigma, St. Louis, MO) in Hanks’ balanced salt solution
(HBSS; Invitrogen, Carlsbad, CA). Pancreatic tissue was recovered and
subjected to a 12-min digestion at 37°C. Subsequently, ice-cold HBSS was
added, and the suspension was vortexed at full speed for 10 s. Islets were
puriﬁed on a discontinuous Ficoll gradient (Sigma) and hand-picked under
a dissection microscope. Islets were used immediately after isolation to
obtain RNA.
Evaluation of cellular stress. To evaluate whether the islets of transgenic
mice showed signs of distress, we determined the levels of expression of
several “stress genes” by quantitative PCR. Primers used were sarcoendoplas-
matic reticulum CA/ATPase type 2, GGCAAGATCCGGGATGAAAT (forward)
and TCCAGACTGCAATGCAAATGA (reverse); GADD153/CHOP [CCAAT/en-
hancer binding protein], TCTCATCCCCAGGAAACGAA (forward) and ATC
TGGAGAGCGAGGGCTTT (reverse); XBP-1, CTTTCATCCAGCCATTGTCTGA
(forward) and GCCCTCATATCCACAGTCACTGT (reverse); activating tran-
scriptionfactor-4,CGAGTTAAGCACATTCCTGGA(forward)andTTCGCTGTT
CAGGAAGCTCAT (reverse); immunoglobulin heavy-chain binding protein,
ACCCCGAGAACACGGTCTT (forward) and GCTGCA CCGAAGGGTCATT
(reverse); and tumor necrosis factor receptor–associated, AAGATGGAG
GCCAAGAATTCC (forward) and AGTCCTGTTAGGTCCACAATAGCTTT
(reverse).
As positive controls, we used islets from wild-type mice (8 weeks of age)
that were treated with a single intraperitoneal injection of streptozotocin
(STZ) (250 mg/kg body wt). Eight hours later, islets were isolated as described
above.
Quantitative real-time PCR. Total RNA was extracted from pooled islets
using the RNeasy maxi kit (Qiagen) according to the manufacturer’s instruc-
tions. Reverse transcription was performed for 3 g RNA. Quantitative PCR
was conducted in duplicate from 25 ng cDNA and with each primer at 0.4
mol/l in a 30-l ﬁnal reaction volume of 1 SYBR Green PCR Master Mix
(Applied Biosystems). PCR cycling conditions were 50°C for 2 min, 95°C for
15 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. Relative expression
levels were calculated as 2Ct ubiquitinCt gene (where Ct is cycle threshold;
for details see ABI PRISM 7700 User Bulletin no. 2; Applied Biosystems) using
ubiquitin RNA as endogenous control.
Protein analysis. CCL2 was measured in serum by ELISA (R&D Systems,
Minneapolis, MN). Enzyme-linked immunosorbent assay (ELISA) assays were
done according to manufacturer’s instructions.
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antibody mixture, erythrocytes were lysed, and cells were ﬁxed with ﬂow
cytometry analysis (FACS) lysis solution (Becton Dickinson, San Jose, CA).
Bone marrow cells were obtained from the tibia and femur bones. Contami-
nating erythrocytes were lysed with ammonium chloride lysis buffer and
samples were stained with antibody mixture for 45 min at 4°C. Antibodies
used in the experiments described here were as follows: anti-CD115 (AFS98),
anti-CD11b (M1/70), anti-CD11c (N418), and anti-F4/80 (BM8) from e-Bio-
science (San Diego CA) and anti-mouse Ly6C (AL-21) from BD Pharmingen
(San Diego, CA). Samples were analyzed in a FACSCanto instrument (Becton
Dickinson). Up to 100,000 events were acquired.
Flow cytometry analysis of the bone marrow perfusate was performed as
follows: The perfusate was centrifuged (200  g for 5 min, 4°C). Erythrocytes
were lysed using hypotonic shock, and the cell pellets were resuspended in
FACS buffer. An aliquot of cells was taken to establish the total number of
leukocytes mobilized over the 60-min period by staining with 2% methylene
blue in 1% acetic acid. Cells were enumerated using an improved Neubauer
Hemocytometer. The remaining leukocytes were stained with the following
monoclonal antibodies: anti-mouse CD115, Gr1, CD3e, and B220. Appropri-
ately conjugated isotype control antibodies were used to calculate back-
ground ﬂuorescence. The samples were then analyzed by ﬂow cytometry (BD
FACSCalibur), and the relative number of cells expressing CD115/Gr1 inter-
mediate (monocytes), Gr1
high (neutrophils), CD3 (T-lymphocytes), and B220
(B-lymphocytes) was calculated.
Statistical analysis. Data are expressed as means 
 SE. One-way ANOVA
and unpaired t test were used to determine statistical signiﬁcance. Differences
were considered signiﬁcant when P 	 0.05.
RESULTS
Levels of CCL2 and frequency of mononuclear inﬁl-
trates in the islets correlate with development of
diabetes. We have previously described the generation of
ﬁve transgenic lines expressing different levels of CCL2 in
the islets (26). We have observed that the number of
inﬂammatory cells recruited to the islets is dependent on
the levels of CCL2 produced by the -cells (26). To
investigate the frequency of mononuclear inﬁltration,
semiquantitative analysis of inﬁltrated islets was per-
formed in pancreata from 4-week-old mice (n  8/group).
No inﬁltrates were found in islets of wild-type mice
regardless of age. In marked contrast, 60, 80, 95, and 100%
of the islets in RIPCCL2 pancreata from lines 251, 10, 254,
and 1, respectively, were inﬁltrated by leukocytes (largely
monocytes and dendritic cells) (Fig. 1A) (26). The inﬁl-
trates were observed predominantly in the periphery of
the islets in lines 251 and 10. Pancreata from mice of lines
254 and 1 showed a severe insulitis, with leukocytes
present in the periphery and within the islets (data not
shown) (26). The frequency and the size of these inﬁltrates
did not change with age. To examine whether an increased
number of inﬁltrated islets led to development of diabetes,
we monitored RIPCCL2 mice and their control littermates
weekly for hyperglycemia. No hyperglycemia was ob-
served in control mice or in transgenic mice of lines 10 and
251 during the ﬁrst 20 weeks of life. In contrast, animals
from lines 254 and 1 (which had higher levels of CCL2 and
an increased number of inﬁltrated islets) became hyper-
glycemic at 4–5 weeks of age. By 16 weeks of age, 80% of
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FIG. 1. Augmented levels of CCL2 in islets of Langerhans lead to an increased number of monocytes in blood, inﬁltrated islets, and spontaneous
diabetes. A: Semiquantitative analysis of islet inﬁltrates in the pancreata from control and RIPCCL2 transgenic mice at 4 weeks of age (n 
8/group). B: Cumulative incidence of diabetes in RIPCL2 mice from lines 251 (n  60), 10 (n  40), 254 (n  95), and 1 (n  31) and from
nontransgenic littermates (n  20). C: Relative numbers of CD115
 cells in blood from wild-type and RIPCCL2 mice (n  20 mice in each line;
t test **P < 0.005, ***P < 0.0001). D: CCL2 levels in the serum of RIPCCL2 mice of lines 251, 10, 254, and 1 and wild-type littermates was analyzed
by ELISA (n  20/line; t test **P < 0.005, ***P < 0.0001).
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line 254 were diabetic (Fig. 1B).
The development of diabetes in several transgenic lines
has been linked to toxicity induced by transgene expres-
sion (28). To test this, we isolated islets from 6- to
8-week-old wild-type and normoglycemic RIPCCL2 mice
and evaluated the expression of genes induced during
cellular stress by quantitative PCR. As a positive control,
we used islets isolated from wild-type mice injected with
STZ. As shown in supplemental Fig. 1A (available in an
online appendix at http://dx.doi.org/10.2337/db08-0625), is-
lets isolated from mice administered STZ, but not those
isolated from RIPCCL2 mice, had increased expression of
stress genes. To exclude the possibility that transgene
expression of CCL2 by -cells led to impaired glucose
tolerance, we performed a glucose tolerance test on
8-week-old control and normoglycemic RIPCCL2 mice.
The glucose levels after intraperitoneal injection of glu-
cose were comparable between wild-type and RIPCCL2
mice (supplemental Fig. 1B), suggesting that overexpres-
sion of CCL2 in the islets did not affect their ability to
respond to a glucose challenge. Together, the results
indicate that expression of CCL2 per se did not lead to
cellular stress or affect the function of the -cells. We
suggest that the development of diabetes was dependent
on the recruitment of myeloid cells by CCL2.
Levels of CCL2 in the islets and blood correlate with
the number of monocytes in circulation. The increased
number of monocytes in the islets could be due to in-
creased efﬁciency in recruitment of a ﬁxed number of
circulating cells or to an increased number of monocytes
in circulation. To determine whether RIPCCL2 mice had
more circulating monocytes, we performed FACS analysis
of peripheral blood (Fig. 1C). Blood monocytes were
deﬁned as a leukocyte population with low side scatter
that expressed the markers CD115, Ly6C, F4/80, and
CD11b. Using these parameters, we found that RIPCCL2
mice had higher numbers of monocytes in circulation than
control mice (10–30 and 5–6%, respectively) (Fig. 1C). We
hypothesized that the increased number of cells in circu-
lation was promoted by CCL2 produced by the islets of the
RIPCCL2 mice. Serum from RIPCCL2 animals from differ-
ent lines (n  20 in each line, nondiabetic) had 3- to 35-fold
more CCL2 than their nontransgenic littermates (n  20)
(Fig. 1D). The levels of CCL2 in serum correlated directly
with the amount of CCL2 produced in the transgenic islets
(26). These results conﬁrm a correlation between in-
creased levels of CCL2 in the tissue and blood and the
number of monocytes in circulation.
CCL2 induces release of monocytes from the bone
marrow. To determine whether CCL2 could exert a direct
effect on the release of monocytes from the bone marrow,
we used an in situ perfusion system of the mouse femoral
bone marrow (29). The femoral artery and vein were
cannulated in situ such that the femoral bone marrow
could be perfused and the leukocytes released from the
bone marrow collected as they exited via the femoral vein.
Vehicle alone (PBS, control mice) or CCL2 was infused for
20 min directly into the mouse femoral artery using a
Minipuls peristaltic pump, and the leukocytes mobilized
from the femoral bone marrow were collected over a
subsequent 60-min perfusion period. The numbers of
monocytes, neutrophils, T-cells, and B-cells released into
the perfusate were determined by ﬂow cytometry. As
shown in Fig. 2, CCL2 induced an increased release of
monocytes from the bone marrow over the 60-min perfu-
sion period compared with controls. The relative number
of monocytes changed from 6% in PBS-infused mice to 13%
in CCL2-infused mice (Fig. 2B). Moreover, CCL2 induced
bone marrow release of 7 10
5 monocytes/ml perfusate,
whereas PBS controls had 2.5 10
5 monocytes/ml perfus-
ate. However, CCL2 infusion did not result in signiﬁcant
changes in the relative numbers of neutrophils (CD115
/
GR-1
), T-cells (CD3
), or B-cells (B220
) (data not
shown). These results support the hypothesis that an
increased concentration of CCL2 in circulation can induce
monocyte release from the bone marrow.
CCL2 promotes monocyte release from the bone
marrow via CCR2. CCL2 is the ligand for the chemokine
receptor CCR2. To demonstrate a tight link between the
monocytosis in the RIPPCCL2 mice and the production of
CCL2 in the periphery, we crossed RIPCCL2 mice (line
254) with CCR2-deﬁcient animals to generate RIPCCL2/
CCR2
/ mice. Deletion of CCR2 led to a signiﬁcant
decrease in the circulating numbers of CD115
/Ly6C

monocytes (Fig. 3A), consistent with previous results (30).
Genetic deletion of CCR2 in RIPCCL2 mice completely
abrogated the monocytosis observed in these mice. FACS
analysis of bone marrow showed that the number of
monocytes in the bone marrow of wild-type mice varies
between 5 and 9%. Similar numbers of monocytes were
obtained in the bone marrow of RIPCCL2 mice. On the
other hand, RIPCCL2/CCR2
/ mice had a larger number
of CD115
/Ly6c
 monocytes than RIPCCL2/CCR2
/
mice (Fig. 3B). Analysis of islets inﬁltrates by immuno-
staining with anti-CD45 and anti-insulin showed that dele-
tion of CCR2 signiﬁcantly reduced the number of CD45

cells in islets of RIPCCL2/CCR2
/ mice relative to
RIPCCL2/CCR2
/ mice (Fig. 3C). Despite the marked
reduction in the number of CD45
 cells, RIPCCL2/
CCR2
/ mice still showed higher numbers of leukocytes
in the pancreatic islets than wild-type mice, suggesting
that leukocytes could still migrate to CCL2-expressing
tissue in the absence of CCR2 as suggested by others
(30,31). None of the RIPCCL2/CCR2
/ mice analyzed
developed diabetes by 16 weeks of age (n  30). These
results indicate that CCR2 is required for effective mobili-
zation of monocytes from the bone marrow in response to
systemically elevated levels of CCL2.
Modulation of the number of circulating monocytes
promotes diabetes in mice expressing low levels of
CCL2 in the islets. One of the predictions of the previous
studies was that an increased number of circulating mono-
cytes could lead to diabetes development if CCL2 was
expressed in the islets. To test this hypothesis, we crossed
RIPCCL2 mice from lines 251 and 10 with animals that
conditionally express the myeloid growth factor Flt3L
upon administration of doxycycline (DOX) (32) (Fig. 4A).
Flt3L is a known growth factor for pluripotent hemopoi-
etic stem cells and progenitor cells (33). Flt3L is also
reported to increase numbers of lymphocytes, granulo-
cytes, and monocytes in peripheral blood (34,35). Animals
with the CCL2 and Flt3L transgenes are referred to as
RIPCCL2/Flt3L mice. First, we analyzed the peripheral
blood from untreated and treated RIPCCL2/Flt3L mice
from lines 251 and 10. As shown in Fig. 4B, the relative
number of CD115
 monocytes changed from 10% in un-
treated mice to 28% in DOX-treated mice in mice from line
251 (unpaired t test P 	 0.0001). Evaluation of CD115

monocytes in blood also showed an increase in the relative
number of those cells from 16 to 35% when RIPCCL2/Flt3L
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unpaired t test P 	 0.0001).
Because the circulating monocyte population increased,
we then determined whether islets from DOX-treated mice
would show increased mononuclear cell inﬁltration. We
examined histological sections of pancreata from un-
treated (DOX) and treated (DOX) double transgenic
mice from both lines. Immunostaining with antibodies
against CD45 and insulin showed inﬁltrates of varying
sizes in islets of untreated (DOX) RIPCCL2/Flt3L mice
from line 251 (Fig. 4D) and line 10 (Fig. 4E), similar to
what was observed in pancreata from RIPCCL2 animals of
each line. In striking contrast, DOX treatment of RIPCCL2/
Flt3L mice led to an increased number of leukocytes
inﬁltrating the islets of double-transgenic mice from lines
251 and 10 (Fig. 4F and G, respectively). Subsequently,
DOX-untreated and -treated RIPCCL2/Flt3L mice were
monitored weekly for onset of hyperglycemia. As ex-
pected, none of the untreated RIPCCL2/Flt3L mice from
line 251 developed diabetes after 10 weeks (Fig. 4H).
However, 5 weeks after DOX treatment, RIPCCL2/Flt3L
mice from line 251 started to show diabetes (70% of the
animals in this group were diabetic after 10 weeks of
treatment). No disease was observed in DOX-treated Flt3L
littermates during this period (Fig. 4H). Strikingly, 100% of
DOX-treated RIPCCL2/Flt3L mice from line 10 developed
diabetes 14 days after DOX treatment (Fig. 4I). None of the
untreated RIPCCL2/Flt3L mice or treated Flt3L mice de-
veloped diabetes during this time (Fig. 4I). Together, these
results suggest that development of diabetes in RIPCCL2
mice depended both on the levels of expression of CCL2 in
the islets and on the number of circulating cells.
Development of diabetes in RIPCCL2 mice does not
depend on T- and B-cells. Because type 1 diabetes is a
Th1-mediated autoimmune process induced by activated
diabetogenic T-cells, the increase in the myeloid cells in
the tissue could favor priming of T-cells or could itself lead
to -cell destruction. To investigate whether T- and B-cells
were required to induce diabetes in RIPCCL2 mice, we
crossed RIPCCL2 mice from line 1 (a line that develops
diabetes with high incidence) with Rag-1
/ mice, which
lack mature T- and B-cells, to generate RIPCCL2/Rag
/
mice. RIPCCL2/Rag
/ mice and their control littermates
(RIPCCL2/Rag
/) were monitored weekly for hypergly-
cemia. As expected, RIPCCL2/Rag
/ mice started to
develop diabetes by 6 weeks of age and reached 60% of
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Rag
/ mice developed diabetes with a similar course, the
incidence of diabetes was signiﬁcantly increased com-
pared with RIPCCL2/Rag
/ mice. This result suggests
that mature T- and B-cells are not necessary for diabetes in
this model, which is dependent primarily on myeloid cells
to induce disease.
DISCUSSION
Type 1 diabetes is an autoimmune disease characterized
by a local inﬂammatory reaction in and around islets
followed by selective destruction of insulin-secreting
-cells (36). Here, we show that accumulation of mono-
cytes in islets of Langerhans is sufﬁcient for induction of
type 1 diabetes. In the model that we have developed,
monocytes accumulate in the islet because of expression
in the -cells of the chemokine CCL2, which acts both
locally and remotely to promote monocyte inﬂux.
While local chemotactic activity has been demonstrated
previously, only recently have chemokines been shown to
modulate release of cells from the bone marrow (29,37).
For instance, the chemokines CCL11 and CXCL1 have
been shown to selectively mobilize eosinophils and neu-
trophils from the bone marrow, respectively (29,37). Mo-
bilization of monocytes from the bone marrow is
controlled mainly by CCR2 (30,31). During inﬂammation it
has been suggested that CCL2 may be involved in this
process (30), but the absence of a reductionist model has
precluded ﬁrm conclusions. Here, we have directly tested
the hypothesis that CCL2 can mobilize cells from the
marrow in a transgenic model in which this chemokine is
overexpressed in a single site (islets of Langerhans). We
show a direct correlation between circulating numbers of
monocytes and levels of CCL2 in tissue and in the blood.
Furthermore, we show that infusion of CCL2 into the
femoral bone marrow of control mice leads to monocyte
mobilization from the femoral bone marrow into the
bloodstream, strongly suggesting that the main mecha-
nism accounting for the monocytosis is the direct release
of monocytes from the bone marrow. The fact that dele-
tion of CCL2 receptor CCR2 in RIPCCL2 mice abrogated
monocytosis further supports an important role for CCR2
in monocyte release from the bone marrow (30).
There are several inﬂammatory conditions in which
CCL2 serum levels correlate with pathogenesis and/or
disease activity, including ischemic stroke and myocardial
infarction (38), rheumatoid arthritis (39), chronic autoim-
mune thyroiditis (40), and HIV (41). Although many of
these studies suggest that CCL2 serum levels could serve
as a parameter to monitor the stage and severity of the
disease, correlations between CCL2 serum levels, the
number of monocytes in circulation, and the extent of
mononuclear cell inﬁltration in the tissues in these pa-
tients have not been analyzed. However, a positive corre-
lation between plasma levels of CCL2 and the number of
circulating CD11b
 cells has been observed in obese mice
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10% in obese and overweight subjects (43). Furthermore,
systemic administration of CCL2 in mice causes accumu-
lation of MOMA-2
 monocytes in collateral arteries and
increases neointimal formation (44). These observations
strongly suggest that changes in plasma levels of CCL2
may lead to changes in the number of monocytes in
circulation and that both of these parameters are indexes
of disease severity.
The mechanisms accounting for monocyte accumula-
tion in chronically inﬂamed tissues are not completely
understood. We propose that one of the factors contribut-
ing to this process is CCL2. In this study, we show that
CCL2 can induce recruitment of monocytes to the islets
and that the number of inﬁltrated islets depends on CCL2
concentration and monocyte availability. These ﬁndings
may have relevance in the context of diabetes because
they suggest a direct role for these cells in the process of
islet destruction. Indirect evidence suggests such a role.
For example, inhibition of macrophage inﬁltration by
silica treatment abolishes lymphocytic insulitis and diabe-
tes development in the model featuring multiple low doses
of STZ (MLDS) (45). Diabetes in the MLDS model can also
be induced in NOD scid/scid mice lacking functional
lymphocytes (46), which offers evidence for the impor-
tance of monocytes.
Although the preponderance of the evidence points to a
critical importance of T-cells in the pathogenesis of type 1
diabetes, we show here that damage to the islets can be
directly caused by monocytes and dendritic cells. Interest-
ingly, the incidence of diabetes in the RIPCCL2/Rag
/
mice was actually higher than that in RIPCCL2/Rag
/
mice. The reasons for the higher incidence of diabetes in
the RIPCCL2/Rag
/ group are not clear, but an intrinsic
augmented activity of monocytes or other innate immune
cells in the Rag
/ background may be reﬂected. In type 1
diabetes, an initial attack by monocytes and dendritic cells
may put in motion a cascade of events leading to expan-
sion of an autoreactive T-cell pool and complete destruc-
tion of the islets. In humans, circulating monocytes from
type 1 and type 2 diabetic patients show an aberrant
cytokine proﬁle when stimulated (47), suggesting that they
may contribute to the initiation or continuation of an
immune attack against the pancreatic -cells. We suggest
that T-cells and macrophages may synergize to mediate
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monocytes in the development of diabetes, an alternative
explanation for our ﬁndings might be that the transgenic
expression of CCL2 was itself toxic to the islets. Arguing
against this hypothesis is the ﬁnding that expression of
several transcription factors associated with -cell apopto-
sis (rev. in 48) did not differ in transgenic or control islets,
suggesting that CCL2 expression did not induce stress in
the islets. Furthermore, transgenic expression of CCL2 did
not impair glucose homeostasis. Before development of
disease, transgenic mice responded to a glucose tolerance
test similarly to control mice. Finally, RIPCCL2 mice
lacking CCR2 did not develop diabetes over time, which
rules out a direct toxic effect of CCL2 as the cause of
diabetes in the RIPCCL2 mice.
We propose that the local concentration of CCL2 and
the number of circulating monocytes play an important
role in the onset of autoimmune diseases. Our group has
shown that expression of CCL2 in the central nervous
system drives monocyte/macrophage accumulation in the
central nervous system without any symptom of neurolog-
ical disease (49). However, those mice develop a severe
demyelinating encephalomyelitis if the numbers of mono-
cytes/macrophages and dendritic cells are altered in the
periphery (34). Here, we show that elevating the number
of monocytes by transgenic expression of Flt3L in
RIPCCL2 lines with lower expression of CCL2 (RIPCCL2/
Flt3L mice) results in increased monocyte inﬁltration of
the islets and diabetes.
In summary, we ﬁnd that the ability of CCL2 to promote
tissue-speciﬁc inﬂux of monocytes is due to two factors:
its capacity to trigger mobilization of monocytes from
bone marrow into circulation and its ability to mediate
inﬂux of monocytes into tissues. These properties are key
for the inﬁltration and subsequent destruction of the islets
of Langerhans in transgenic mice. The relevance of these
mechanisms for autoimmune disease in NOD mice and
humans is currently under investigation.
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